CN101790380B - 合成tlr激动剂的缀合物及其应用 - Google Patents

合成tlr激动剂的缀合物及其应用 Download PDF

Info

Publication number
CN101790380B
CN101790380B CN2008800115258A CN200880011525A CN101790380B CN 101790380 B CN101790380 B CN 101790380B CN 2008800115258 A CN2008800115258 A CN 2008800115258A CN 200880011525 A CN200880011525 A CN 200880011525A CN 101790380 B CN101790380 B CN 101790380B
Authority
CN
China
Prior art keywords
purposes
alkyl
illness
condition
tlr7
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2008800115258A
Other languages
English (en)
Chinese (zh)
Other versions
CN101790380A (zh
Inventor
D·A·卡森
H·B·科塔姆
W·兰希多拉
吴正宁
G·A·丹尼尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CN101790380A publication Critical patent/CN101790380A/zh
Application granted granted Critical
Publication of CN101790380B publication Critical patent/CN101790380B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN2008800115258A 2007-02-07 2008-02-07 合成tlr激动剂的缀合物及其应用 Active CN101790380B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88869907P 2007-02-07 2007-02-07
US60/888,699 2007-02-07
PCT/US2008/001631 WO2008115319A2 (en) 2007-02-07 2008-02-07 Conjugates of synthetic tlr agonists and uses therefor

Publications (2)

Publication Number Publication Date
CN101790380A CN101790380A (zh) 2010-07-28
CN101790380B true CN101790380B (zh) 2013-07-10

Family

ID=39766655

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008800115258A Active CN101790380B (zh) 2007-02-07 2008-02-07 合成tlr激动剂的缀合物及其应用

Country Status (18)

Country Link
US (3) US8357374B2 (enExample)
EP (2) EP2125007B9 (enExample)
JP (2) JP5425642B2 (enExample)
KR (1) KR20090109121A (enExample)
CN (1) CN101790380B (enExample)
AU (1) AU2008227128B2 (enExample)
BR (1) BRPI0807196A2 (enExample)
CA (1) CA2677733A1 (enExample)
DK (1) DK2510946T3 (enExample)
EA (1) EA019151B1 (enExample)
ES (2) ES2552471T3 (enExample)
HU (1) HUE025555T2 (enExample)
IL (1) IL200240A (enExample)
PL (2) PL2125007T3 (enExample)
PT (1) PT2510946E (enExample)
SI (1) SI2510946T1 (enExample)
WO (1) WO2008115319A2 (enExample)
ZA (1) ZA200906094B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105311032A (zh) * 2015-11-09 2016-02-10 深圳大学 Tlr7激动剂与酪氨酸激酶抑制剂联用在制备抗肿瘤药物中的应用
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101304748A (zh) 2005-08-22 2008-11-12 加利福尼亚大学董事会 Tlr激动剂
EP2700638A1 (en) 2006-05-31 2014-02-26 The Regents Of the University of California Purine analogs
HUE025555T2 (en) 2007-02-07 2016-02-29 Univ California Conjugates and applications of synthetic tlr agonists
WO2009049365A1 (en) * 2007-10-15 2009-04-23 Cooperative Research Centre For Asthma A method of prophylaxis and agents for use therein
US20090202626A1 (en) * 2008-02-07 2009-08-13 Carson Dennis A Treatment of bladder diseases with a tlr7 activator
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
EP2396328A2 (en) 2009-02-11 2011-12-21 The Regents of The University of California Toll-like receptor modulators and treatment of diseases
WO2010138193A2 (en) * 2009-05-27 2010-12-02 Selecta Biosciences, Inc. Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents
CA2777824C (en) 2009-10-22 2016-11-29 Gilead Sciences, Inc. Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
EP2563401A1 (en) * 2010-04-30 2013-03-06 Telormedix SA Methods for inducing an immune response
CA2797315C (en) * 2010-04-30 2018-09-11 Telormedix Sa Phospholipid drug analogs
US20130202629A1 (en) * 2010-04-30 2013-08-08 The Regents Of The University Of California Uses of phospholipid conjugates of synthetic tlr7 agonists
US9050319B2 (en) 2010-04-30 2015-06-09 Telormedix, Sa Phospholipid drug analogs
US20110293700A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Nanocarrier compositions with uncoupled adjuvant
US20120083473A1 (en) 2010-09-21 2012-04-05 Johanna Holldack Treatment of conditions by toll-like receptor modulators
US20140031250A1 (en) 2010-10-07 2014-01-30 David Tsai Ting Biomarkers of Cancer
EP2640190A4 (en) 2010-11-05 2016-05-11 Selecta Biosciences Inc MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS
MY170941A (en) 2011-04-08 2019-09-19 Janssen Sciences Ireland Uc Pyrimidine derivatives for the treatment of viral infections
CN103582496B (zh) 2011-06-03 2016-05-11 3M创新有限公司 具有聚乙二醇链段的异双官能连接基以及由其制成的免疫应答调节剂缀合物
WO2012167081A1 (en) * 2011-06-03 2012-12-06 3M Innovative Properties Company Hydrazino 1h-imidazoquinolin-4-amines and conjugates made therefrom
CN109172819A (zh) 2011-07-29 2019-01-11 西莱克塔生物科技公司 产生体液和细胞毒性t淋巴细胞（ctl）免疫应答的合成纳米载体
IN2014MN00862A (enExample) 2011-11-09 2015-04-17 Janssen R & D Ireland
ES2731524T3 (es) 2012-04-05 2019-11-15 Massachusetts Inst Technology Composiciones inmunoestimuladoras y métodos de uso de las mismas
AU2013288600B2 (en) 2012-07-13 2017-06-29 Janssen Sciences Ireland Uc Macrocyclic purines for the treatment of viral infections
CN103566377A (zh) * 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
WO2014052828A1 (en) 2012-09-27 2014-04-03 The Regents Of The University Of California Compositions and methods for modulating tlr4
CN111420045B (zh) * 2012-10-10 2023-03-31 深圳大学 免疫受体调节剂偶联体及其制备方法和应用、制备其的偶联前体以及合成偶联前体的化合物
MX365114B (es) 2012-10-10 2019-05-23 Janssen Sciences Ireland Uc Derivados pirrolo[3,2-d]pirimidinicos para el tratamiento de infecciones viricas y otras enfermedades.
MY171115A (en) 2012-11-16 2019-09-26 Janssen Sciences Ireland Uc Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
UA118751C2 (uk) 2013-02-21 2019-03-11 ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі Похідні 2-амінопіримідину для лікування вірусних інфекцій
WO2014131023A1 (en) * 2013-02-25 2014-08-28 The Scripps Research Institute Neoseptins: small molecule adjuvants
CN105263513A (zh) * 2013-03-14 2016-01-20 王荣福 调控调节性t细胞功能的方法和组合物
WO2014144365A1 (en) * 2013-03-15 2014-09-18 University Of Maryland, College Park Nano-liposomal formulations and methods of use
ES2625456T3 (es) * 2013-03-29 2017-07-19 Janssen Sciences Ireland Uc Desazapurinonas macrocíclicas para el tratamiento de infecciones víricas
JP6377139B2 (ja) 2013-05-24 2018-08-22 ヤンセン・サイエンシズ・アイルランド・ユーシー ウイルス感染症およびさらなる疾患の処置のためのピリドン誘導体
PL3030563T3 (pl) 2013-06-27 2018-01-31 Janssen Sciences Ireland Uc Pochodne pirolo [3,2-d] pirymidyny do leczenia zakażeń wirusowych i innych chorób
EP3027624B1 (en) 2013-07-30 2018-09-12 Janssen Sciences Ireland UC Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
WO2015023858A2 (en) * 2013-08-16 2015-02-19 The Regents Of The University Of California Uses of phospholipid conjugates of synthetic tlr7 agonists
GB201321242D0 (en) 2013-12-02 2014-01-15 Immune Targeting Systems Its Ltd Immunogenic compound
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
CA2936377A1 (en) 2014-01-10 2015-07-16 Shanghai Birdie Biotech, Inc. Compounds and compositions for treating egfr expressing tumors
WO2015200697A1 (en) 2014-06-25 2015-12-30 The General Hospital Corporation Targeting human satellite ii (hsatii)
EP4001311B1 (en) 2014-07-09 2025-11-05 Birdie Biopharmaceuticals Inc. Anti-pd-l1/pd-1 combinations for treating tumors
WO2016022700A2 (en) 2014-08-06 2016-02-11 The Scripps Research Institute Tlr-independent small molecule adjuvants
PL3190113T3 (pl) * 2014-08-15 2021-10-25 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Związki pirolopirymidynowe stosowane jako agonista TLR7
CN112546238A (zh) 2014-09-01 2021-03-26 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
US10034901B2 (en) 2015-01-22 2018-07-31 University Of Massachusetts Cancer immunotherapy
MX375989B (es) * 2015-05-26 2025-03-07 Ohio State Innovation Foundation Estrategia de vacuna basada en nanoparticulas contra el virus de la influenza porcina.
CN108139375A (zh) 2015-06-26 2018-06-08 贝斯以色列女执事医疗中心股份有限公司 靶向髓样衍生的抑制细胞中的四跨膜蛋白33(tspan33)的癌症疗法
EP3355933B1 (en) * 2015-09-29 2020-05-06 Sumitomo Dainippon Pharma Co., Ltd. Adenine conjugate compounds and their use as vaccine adjuvants
CN105315281B (zh) * 2015-11-16 2017-04-19 深圳大学 化合物i和化合物ii及其制备方法和应用
CN115554406A (zh) 2016-01-07 2023-01-03 博笛生物科技有限公司 用于治疗肿瘤的抗-cd20组合
CN115350279A (zh) 2016-01-07 2022-11-18 博笛生物科技有限公司 用于治疗肿瘤的抗-her2组合
CN115252792A (zh) 2016-01-07 2022-11-01 博笛生物科技有限公司 用于治疗肿瘤的抗-egfr组合
AU2017268175B2 (en) 2016-05-16 2023-02-23 Access To Advanced Health Institute PEGylated liposomes and methods of use
SG11201811448RA (en) 2016-07-01 2019-01-30 Janssen Sciences Ireland Unlimited Co Dihydropyranopyrimidines for the treatment of viral infections
WO2018013924A1 (en) 2016-07-15 2018-01-18 Massachusetts Institute Of Technology Synthetic nanoparticles for delivery of immunomodulatory compounds
EA038646B1 (ru) 2016-09-29 2021-09-28 Янссен Сайенсиз Айрлэнд Анлимитед Компани Пиримидиновые пролекарства для лечения вирусных инфекций и других заболеваний
WO2018077385A1 (en) * 2016-10-25 2018-05-03 Biontech Rna Pharmaceuticals Gmbh Dose determination for immunotherapeutic agents
US11459568B2 (en) 2016-10-31 2022-10-04 University Of Massachusetts Targeting microRNA-101-3p in cancer therapy
WO2018089688A1 (en) 2016-11-09 2018-05-17 Jinjun Shi Restoration of tumor suppression using mrna-based delivery system
EP3551047A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CA3046019A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a tlr modulator
JP7161760B2 (ja) * 2017-02-03 2022-10-27 国立大学法人東北大学 複素環化合物
CN118515666A (zh) 2017-04-27 2024-08-20 博笛生物科技有限公司 2-氨基-喹啉衍生物
CA3067268A1 (en) 2017-06-23 2018-12-27 Birdie Biopharmaceuticals, Inc. Crystalline resiquimod monosulfate anhydrate and its preparation and uses
US20200163880A1 (en) 2017-07-13 2020-05-28 Danmarks Tekniske Universitet Cationic liposomes
US10472361B2 (en) 2017-08-16 2019-11-12 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
US10494370B2 (en) 2017-08-16 2019-12-03 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
US10457681B2 (en) 2017-08-16 2019-10-29 Bristol_Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
US10487084B2 (en) 2017-08-16 2019-11-26 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
US10508115B2 (en) 2017-08-16 2019-12-17 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
US11814623B2 (en) 2018-01-30 2023-11-14 University Of Massachusetts Methods of treating a wound using epigenetic regulation
JP2021512956A (ja) 2018-02-06 2021-05-20 ザ ジェネラル ホスピタル コーポレイション 腫瘍免疫応答のバイオマーカーとしてのリピートｒｎａ
TW202415645A (zh) 2018-03-01 2024-04-16 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途
CN110317202B (zh) * 2018-03-30 2021-12-24 江苏恒瑞医药股份有限公司 氰基吡咯并杂芳基类衍生物、其制备方法及其在医药上的应用
CN115192726A (zh) 2018-04-03 2022-10-18 深圳大学 免疫激动剂靶向化合物的合成及其应用
EP3774806A1 (en) * 2018-04-13 2021-02-17 GlaxoSmithKline Biologicals SA Tlr7 and / or tlr8 agonists
WO2019196918A1 (zh) * 2018-04-13 2019-10-17 罗欣药业(上海)有限公司 五元杂环并嘧啶类化合物、药物组合物及用途
US11485741B2 (en) 2018-04-24 2022-11-01 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (TLR7) agonists
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
BR112021010717A2 (pt) * 2018-12-17 2021-08-31 Eisai R&D Management Co., Ltd. Formulação que compreende lipossomas
WO2020163370A1 (en) 2019-02-04 2020-08-13 Codiak Biosciences, Inc. Membrane protein scaffolds for exosome engineering
KR20220035870A (ko) * 2019-03-14 2022-03-22 더 리전트 오브 더 유니버시티 오브 캘리포니아 백신 어주번트로서의 tlr4 및 tlr7 리간드 제제
US12453777B2 (en) 2019-03-20 2025-10-28 Massachusetts Institute Of Technology Uses of amphiphiles in immune cell therapy and compositions therefor
US20240108747A1 (en) 2019-03-21 2024-04-04 Lonza Sales Ag Extracellular vesicle conjugates and uses thereof
US12233356B2 (en) 2019-03-21 2025-02-25 Lonza Sales Ag Process for preparing extracellular vesicles
SG11202109702QA (en) 2019-03-21 2021-10-28 Codiak Biosciences Inc Extracellular vesicles for vaccine delivery
WO2021003445A1 (en) 2019-07-03 2021-01-07 Codiak Biosciences, Inc. Extracellular vesicles targeting t cells and uses thereof
US20230181758A1 (en) 2019-07-03 2023-06-15 Codiak Biosciences, Inc. Extracellular vesicles targeting dendritic cells and uses thereof
CN114514015B (zh) * 2019-09-19 2025-01-07 丹麦科技大学 免疫刺激胶束组合物
EP4034081A1 (en) 2019-09-25 2022-08-03 Codiak BioSciences, Inc. Extracellular vesicle compositions
AU2020407871A1 (en) * 2019-12-20 2022-06-30 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing toll-like receptor ("TLR") agonist prodrugs useful in the treatment of cancer and methods thereof
JP2023512208A (ja) 2020-01-27 2023-03-24 ブリストル－マイヤーズ スクイブ カンパニー トール様受容体７（ＴＬＲ７）アゴニストとしての１Ｈ－ピラゾロ［４，３－ｄ］ピリミジン化合物
KR20220132594A (ko) 2020-01-27 2022-09-30 브리스톨-마이어스 스큅 컴퍼니 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
KR20220132590A (ko) 2020-01-27 2022-09-30 브리스톨-마이어스 스큅 컴퍼니 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
US20230131192A1 (en) 2020-01-27 2023-04-27 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
CN115151548A (zh) 2020-01-27 2022-10-04 百时美施贵宝公司 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物
WO2021154661A1 (en) 2020-01-27 2021-08-05 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
EP4097106A1 (en) 2020-01-27 2022-12-07 Bristol-Myers Squibb Company 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists
US20230122249A1 (en) 2020-01-27 2023-04-20 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
US20230127326A1 (en) 2020-01-27 2023-04-27 Bristol-Myers Squibb Company C3-SUBSTITUTED 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
US11179473B2 (en) 2020-02-21 2021-11-23 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
WO2021174024A1 (en) 2020-02-28 2021-09-02 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
EP4117717A1 (en) 2020-03-13 2023-01-18 Codiak BioSciences, Inc. Extracellular vesicles for treating neurological disorders
EP4121450A2 (en) 2020-03-20 2023-01-25 Codiak BioSciences, Inc. Extracellular vesicles for therapy
WO2021231942A1 (en) * 2020-05-15 2021-11-18 The Board Of Trustees Of The Leland Stanford Junior University Toll-like receptor (tlr) agonist nanoparticles and uses thereof
WO2021237100A1 (en) 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Methods of targeting extracellular vesicles to lung
US20230220068A1 (en) 2020-06-05 2023-07-13 Codiak Biosciences, Inc. Anti-transferrin extracellular vesicles
CN111892648B (zh) * 2020-06-08 2022-08-26 中国科学院上海药物研究所 偶联tlr7激动剂的新型冠状病毒多肽疫苗及其应用
CN116209678A (zh) 2020-07-01 2023-06-02 安尔士制药公司 抗asgr1抗体缀合物及其用途
AU2021300632A1 (en) 2020-07-02 2023-02-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of achieving HIV viral remission using long-acting antiretroviral agents
WO2022066883A1 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Extracellular vesicles comprising kras antigens and uses thereof
EP4216993A2 (en) 2020-09-23 2023-08-02 Codiak BioSciences, Inc. Methods of producing extracellular vesicles
WO2022066928A2 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Process for preparing extracellular vesicles
JP2023546205A (ja) * 2020-10-21 2023-11-01 ユニヴェルザ ヴィ リュブリャナ コンジュゲートｔｌｒ７およびｎｏｄ２アゴニスト
US20240197759A1 (en) 2021-03-25 2024-06-20 Danmarks Tekniske Universitet Immune stimulating nanoparticle composition
CN114391102B (zh) * 2021-05-27 2025-02-14 中科蓝华(广州)生物医药技术有限公司 一种分析cd303+树突状细胞亚群表型和功能的方法及试剂盒
WO2023081232A1 (en) * 2021-11-03 2023-05-11 Adcentrx Therapeutics Inc. Drug conjugates and methods of preparing and using the same
CN116162088B (zh) * 2022-12-14 2025-03-11 江苏省农业科学院 一种Toll样受体7激动剂纳米颗粒及其制备方法与应用

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
CA1271477A (en) 1983-11-18 1990-07-10 John F. Gerster 1h-imidazo[4,5-c]quinolin-4-amines
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US5736553A (en) 1988-12-15 1998-04-07 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo 4,5-C!quinolin-4-amine
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5037986A (en) 1989-03-23 1991-08-06 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
NZ232740A (en) 1989-04-20 1992-06-25 Riker Laboratories Inc Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
ATE121088T1 (de) 1990-10-05 1995-04-15 Minnesota Mining & Mfg Verfahren zur herstellung von imidazo(4,5- c>chinolin-4-aminen.
US5175296A (en) 1991-03-01 1992-12-29 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5648516A (en) 1994-07-20 1997-07-15 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5525606A (en) 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
DE19505168A1 (de) 1995-02-16 1996-08-22 Boehringer Mannheim Gmbh Spezifische Lipidkonjugate von Nucleosid-Diphosphonaten und deren Verwendung als Arzneimittel
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5693811A (en) 1996-06-21 1997-12-02 Minnesota Mining And Manufacturing Company Process for preparing tetrahdroimidazoquinolinamines
US5741908A (en) 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
DE19637209B4 (de) 1996-09-12 2006-12-14 Siemens Ag Verfahren zum Steuern des Antriebsstrangs eines Kraftfahrzeugs und integrierte Antriebsstrangsteuerung
CZ294563B6 (cs) 1996-10-25 2005-02-16 Minnesota Mining And Manufacturing Company Sloučeniny představující modifikátory imunitní odezvy při léčení nemocí mediovaných TH2 buňkami a nemocí odvozených
ATE318143T1 (de) 1996-10-25 2006-03-15 Gilead Sciences Inc Gefaesszellen wachstumsfaktor (vegf) nukleinsaureligand-komplexe
JPH10298181A (ja) 1997-04-25 1998-11-10 Sumitomo Pharmaceut Co Ltd タイプ２ヘルパーｔ細胞選択的免疫応答抑制剤
DE69824632T2 (de) 1997-11-12 2005-06-09 Mitsubishi Chemical Corp. Purinderivate und medikamente, welche dieselben als aktiven bestandteil enthalten
CA2311742C (en) 1997-11-28 2009-06-16 Sumitomo Pharmaceuticals Co., Ltd. 6-amino-9-benzyl-8-hydroxypurine derivatives
JP4189048B2 (ja) 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
US7001609B1 (en) 1998-10-02 2006-02-21 Regents Of The University Of Minnesota Mucosal originated drug delivery systems and animal applications
US20020058674A1 (en) 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
SK287112B6 (sk) 1999-01-08 2009-12-07 3M Innovative Properties Company Použitie zlúčeniny modifikujúcej imunitnú odpoveď pri liečení cervikálnej dysplázie
US6486168B1 (en) 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
IL150061A0 (en) 1999-12-17 2002-12-01 Ariad Pharma Inc Purine derivatives
JP2004501062A (ja) 1999-12-17 2004-01-15 アライアッド・ファーマシューティカルズ・インコーポレーテッド 新規プリン類
EP1244668B1 (en) 2000-01-07 2006-04-05 Universitaire Instelling Antwerpen Purine derivatives, process for their preparation and use thereof
US6733764B2 (en) 2000-06-14 2004-05-11 Alain Martin Immunostimulator anti-cancer compounds and methods for their use in the treatment of cancer
JP2004510961A (ja) 2000-09-15 2004-04-08 ビルコ・ビーブイビーエイ 疾患の処置のための薬物療法を最適化するシステムおよび方法
GB0023008D0 (en) 2000-09-20 2000-11-01 Glaxo Group Ltd Improvements in vaccination
US20030008015A1 (en) 2000-10-11 2003-01-09 Levisage Catherine S. Polymer controlled delivery of a therapeutic agent
US20020127224A1 (en) 2001-03-02 2002-09-12 James Chen Use of photoluminescent nanoparticles for photodynamic therapy
DK1385823T3 (da) 2001-04-09 2007-03-26 Novartis Vaccines & Diagnostic Guanidinoforbindelser som melanocortin-4-receptor- (MC4-R) -agonister
KR100892614B1 (ko) 2001-04-17 2009-04-09 다이닛본 스미토모 세이야꾸 가부시끼가이샤 신규 아데닌 유도체
EP1572067A4 (en) 2001-05-18 2009-05-13 Sirna Therapeutics Inc CONJUGATES AND COMPOSITIONS FOR CELLULAR RELEASE
ES2247356T3 (es) 2001-06-29 2006-03-01 Cv Therapeutics, Inc. Derivados de purina com antagonistas del receptor a2b de adenosina.
WO2003037860A2 (en) 2001-10-30 2003-05-08 Conforma Therapeutics Corporation Purine analogs having hsp90-inhibiting activity
GB0206461D0 (en) 2002-03-19 2002-05-01 Glaxo Group Ltd Improvements in vaccination
DK1545597T3 (da) 2002-08-15 2011-01-31 3M Innovative Properties Co Immunstimulerende sammensætninger og fremgangsmåde til stimulering af en immunrespons
NZ539064A (en) 2002-09-27 2007-09-28 Dainippon Sumitomo Pharma Co Novel adenine compound and use thereof
JP2004137157A (ja) 2002-10-16 2004-05-13 Sumitomo Pharmaceut Co Ltd 新規アデニン誘導体を有効成分として含有する医薬
US20040202663A1 (en) 2003-01-28 2004-10-14 Shanghai Sunway Biotech Co., Ltd. Therapy for primary and metastatic cancers
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
US20050004144A1 (en) 2003-04-14 2005-01-06 Regents Of The University Of California Combined use of IMPDH inhibitors with toll-like receptor agonists
US20050059613A1 (en) 2003-07-08 2005-03-17 Bahram Memarzadeh Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium
WO2005020892A2 (en) 2003-08-08 2005-03-10 Mitochroma Research, Inc. Pharmaceutical compositions and methods for metabolic modulation
CA2537450C (en) 2003-09-05 2012-04-17 Anadys Pharmaceuticals, Inc. Administration of tlr7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus
JP2005089334A (ja) 2003-09-12 2005-04-07 Sumitomo Pharmaceut Co Ltd ８−ヒドロキシアデニン化合物
EA010160B1 (ru) 2003-09-18 2008-06-30 Конформа Терапьютикс Корпорейшн Новые гетероциклические соединения - ингибиторы hsp90 и способы их получения
FR2863890B1 (fr) 2003-12-19 2006-03-24 Aventis Pasteur Composition immunostimulante
US20050266067A1 (en) 2004-03-02 2005-12-01 Shiladitya Sengupta Nanocell drug delivery system
ES2563952T3 (es) 2004-03-26 2016-03-16 Sumitomo Dainippon Pharma Co., Ltd. Compuesto de 8-oxoadenina 9-sustituido
EP1728792A4 (en) * 2004-03-26 2010-12-15 Dainippon Sumitomo Pharma Co 8-OXOADENINE COMPOUND
WO2006054129A1 (en) 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
PL1819230T3 (pl) 2004-12-07 2013-02-28 Univ Miami Makrocząstki pochodzące z czerwonych krwinek jako czynniki hemostatyczne do kontrolowania krwotoku i do leczenia zaburzeń krwawienia
CN101146810A (zh) 2005-03-21 2008-03-19 菲尔若国际公司 制备1-取代的1H-咪唑并[4,5-c]喹啉-4-胺化合物的方法及其中间体
US20070292418A1 (en) 2005-04-26 2007-12-20 Eisai Co., Ltd. Compositions and methods for immunotherapy
CN101304748A (zh) 2005-08-22 2008-11-12 加利福尼亚大学董事会 Tlr激动剂
JPWO2007034817A1 (ja) 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規アデニン化合物
EP1939201A4 (en) * 2005-09-22 2010-06-16 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
AU2006294528A1 (en) * 2005-09-27 2007-04-05 Coley Pharmaceutical Gmbh Modulation of TLR-mediated immune responses using adaptor oligonucleotides
US20070100146A1 (en) 2005-11-03 2007-05-03 Trevor Dzwiniel Process for the preparation of imidazo[4,5-c]-quinolin-4-amines
EP2700638A1 (en) 2006-05-31 2014-02-26 The Regents Of the University of California Purine analogs
US8338593B2 (en) 2006-07-07 2012-12-25 Gilead Sciences, Inc. Modulators of toll-like receptor 7
US7902187B2 (en) 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
AR063142A1 (es) 2006-10-04 2008-12-30 Pharmacopeia Inc Derivados de 2-(bencimidazolil) purina y purinonas 6-sustituidas utiles como inmunosupresores,y composiciones farmaceuticas que los contienen.
HUE025555T2 (en) 2007-02-07 2016-02-29 Univ California Conjugates and applications of synthetic tlr agonists
CA2691444C (en) 2007-06-29 2016-06-14 Gilead Sciences, Inc. Purine derivatives and their use as modulators of toll-like receptor 7
WO2009052310A1 (en) 2007-10-16 2009-04-23 Cv Therapeutics, Inc A3 adenosine receptor antagonists
US20090202626A1 (en) 2008-02-07 2009-08-13 Carson Dennis A Treatment of bladder diseases with a tlr7 activator
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
EP2396328A2 (en) 2009-02-11 2011-12-21 The Regents of The University of California Toll-like receptor modulators and treatment of diseases
CA2777824C (en) 2009-10-22 2016-11-29 Gilead Sciences, Inc. Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
EP2563401A1 (en) 2010-04-30 2013-03-06 Telormedix SA Methods for inducing an immune response
CA2797315C (en) 2010-04-30 2018-09-11 Telormedix Sa Phospholipid drug analogs
US20130202629A1 (en) 2010-04-30 2013-08-08 The Regents Of The University Of California Uses of phospholipid conjugates of synthetic tlr7 agonists
CN105999275A (zh) 2010-09-01 2016-10-12 诺华有限公司 免疫增强剂吸附不溶性金属离子
US20120083473A1 (en) 2010-09-21 2012-04-05 Johanna Holldack Treatment of conditions by toll-like receptor modulators

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HIV Gag protein conjugated to a toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8(+) T cell responses in nonhuman primates;WILLE-REECE ULRIKE ET AL;《 PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA》;20051031;第102卷(第72期);15190-15194 *
Synthesis and immunostimulatory activity of 8-substituted amino 9-benzyladenines as potent Toll-like receptor 7 agonists;JIN ET AL;《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE》;20060901;第16卷(第17期);4559-4563 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105311032A (zh) * 2015-11-09 2016-02-10 深圳大学 Tlr7激动剂与酪氨酸激酶抑制剂联用在制备抗肿瘤药物中的应用
CN105311032B (zh) * 2015-11-09 2018-09-25 深圳大学 Tlr7激动剂与酪氨酸激酶抑制剂联用在制备抗肿瘤药物中的应用
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms

Also Published As

Publication number Publication date
WO2008115319A2 (en) 2008-09-25
WO2008115319A3 (en) 2009-03-05
JP2010518082A (ja) 2010-05-27
US8790655B2 (en) 2014-07-29
US9050376B2 (en) 2015-06-09
EP2510946B1 (en) 2015-08-05
ZA200906094B (en) 2011-12-28
KR20090109121A (ko) 2009-10-19
US8357374B2 (en) 2013-01-22
EP2125007B1 (en) 2014-01-08
HK1177886A1 (en) 2013-08-30
US20140302120A1 (en) 2014-10-09
ES2456964T9 (es) 2014-07-17
JP5425642B2 (ja) 2014-02-26
EA019151B1 (ru) 2014-01-30
PT2510946E (pt) 2015-11-23
ES2456964T3 (es) 2014-04-24
AU2008227128A1 (en) 2008-09-25
PL2510946T3 (pl) 2015-12-31
EP2510946A1 (en) 2012-10-17
IL200240A (en) 2014-04-30
CA2677733A1 (en) 2008-09-25
BRPI0807196A2 (pt) 2014-06-03
PL2125007T3 (pl) 2014-07-31
HK1138767A1 (en) 2010-09-03
ES2552471T3 (es) 2015-11-30
HUE025555T2 (en) 2016-02-29
JP2013127004A (ja) 2013-06-27
EP2125007B9 (en) 2014-04-16
IL200240A0 (en) 2010-04-29
AU2008227128B2 (en) 2012-12-06
CN101790380A (zh) 2010-07-28
US20120148660A1 (en) 2012-06-14
DK2510946T3 (en) 2015-11-02
US20130156807A1 (en) 2013-06-20
SI2510946T1 (sl) 2015-12-31
EP2125007A2 (en) 2009-12-02
EA200901078A1 (ru) 2010-06-30

Similar Documents

Publication Publication Date Title
CN101790380B (zh) 合成tlr激动剂的缀合物及其应用
US9359360B2 (en) TLR agonists
US20130202629A1 (en) Uses of phospholipid conjugates of synthetic tlr7 agonists
JP2014129425A (ja) Ｔｌｒ７活性化物質による膀胱の疾患の治療
HK1177886B (en) Conjugates of synthetic tlr agonists and uses therefor
HK1138767B (en) Conjugates of synthetic tlr agonists and uses therefor
AU2006283524B2 (en) TLR agonists
HK1126114A (en) Tlr agonists

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant